Novogene Co., Ltd. (SHA:688315)

China flag China · Delayed Price · Currency is CNY
14.27
-0.15 (-1.04%)
At close: Mar 9, 2026
-20.37%
Market Cap 5.78B
Revenue (ttm) 2.17B
Net Income (ttm) 175.21M
Shares Out 405.06M
EPS (ttm) 0.43
PE Ratio 33.13
Forward PE 27.98
Dividend 0.05 (0.35%)
Ex-Dividend Date Jun 10, 2025
Volume 3,535,854
Average Volume 3,710,492
Open 14.13
Previous Close 14.42
Day's Range 14.04 - 14.32
52-Week Range 11.92 - 19.33
Beta 0.82
RSI 39.96
Earnings Date Apr 15, 2026

About Novogene

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcripto... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 2,190
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688315
Full Company Profile

Financial Performance

In 2024, Novogene's revenue was 2.11 billion, an increase of 5.45% compared to the previous year's 2.00 billion. Earnings were 196.79 million, an increase of 10.52%.

Financial Statements

News

There is no news available yet.